Amneal Pharmaceuticals has announced the acquisition of Puniska Healthcare for approximately Rs 700 crore. This acquisition will expand the company’s injectables manufacturing facilities and this will support the American and other international markets.

Amneal Pharmaceuticals, Inc. headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and speciality drug products. The company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the US.

Puniska includes a 293,000 square foot, state-of-the-art manufacturing facility in Ahmedabad, India, with several sterile injectable production lines. Production capabilities include robotic, aseptic and lyophilize vial lines, emulsion line, and large-volume parenteral bag lines.

“Today we are pleased to announce the acquisition of Puniska, and we welcome the Puniska team to the Amneal family. This acquisition is a pivotal step that meaningfully enhances our injectables capabilities for the US market and enables international expansion, including in India, as we look to become a leading player in the global injectables market,” said Chirag and Chintu Patel, co-chief executive officers. “Puniska’s ability to manufacture high volume and complex products will enable Amneal to build on our robust portfolio and pipeline and contribute to the rapid growth in our injectables business, which we project will more than double by 2025.”

Since establishing local operations in 2008, Amneal has built a large and growing presence in India through over US $ 300 million of capital investments and acquisitions.